Clinical Trial Update: Study of Icrucumab (IMC-18F1) or Ramucirumab Drug Product (DP) in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Icrucumab or Ramucirumab in combination with capecitabine for previously treated breast cancer; study completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Icrucumab (IMC-18F1) (icrucumab)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-08-14